Quince Therapeutics Notified of Nasdaq Noncompliance Over Negative Equity

What Happened
Quince Therapeutics, Inc. (QNCX) filed an 8‑K (Item 3.01) disclosing that on August 31, 2026 Nasdaq notified the company it is not in compliance with Nasdaq Listing Rule 5450(b)(1)(A) because the company reported stockholders’ equity of ($35,324,000) for the quarter ended June 30, 2026. The notice does not affect current trading — QNCX common stock continues to trade on the Nasdaq Global Select Market under the symbol “QNCX.”

Key Details

• Nasdaq notice dated August 31, 2026; 8‑K filed September 4, 2026.
• Reported stockholders’ equity: ($35,324,000) versus the $10,000,000 minimum required.
• Company has 45 calendar days (until October 15, 2026) to submit a plan to regain compliance; Nasdaq may grant an extension up to 180 days (until February 27, 2027) if the plan is accepted.
• Company disclosed in its August 25, 2026 proxy (DEF14A) that it filed an Initial Listing Application with Nasdaq and, if approved along with required shareholder actions, expects a name change to “IRulya Therapeutics Inc.” and a symbol change to “IRLA.”

Why It Matters
A Nasdaq noncompliance notice is material because the company must restore at least $10 million in stockholders’ equity or obtain Nasdaq’s acceptance of a remediation plan to avoid potential delisting procedures. While trading continues and the company can appeal or seek extensions, investors should monitor upcoming filings, the company’s compliance plan, the proxy vote outcomes, and any capital‑raising or restructuring steps the company pursues — these actions could affect the company’s financial position, ticker/name, and shareholder value.